Amelia WardThe NHS awarded a £60,000 research grant in April 2026 to Aston University and Sandwell & West Birmingham NHS Trust to study whether GLP-1 receptor agonists — the class of drugs that includes semaglutide, sold as Ozempic and Wegovy — can effectively treat polycystic ovary syndrome. At the same time, the National Institute for Health and Care Excellence is expected to publish new PCOS clinical guidelines this year, following a landmark 2025 report from the charity Verity documenting systemic failures in diagnosis and care across the UK. For the estimated 1 in 10 women of reproductive age living with PCOS, the question is what this moment means for their care.
What Is PCOS and Why Is It So Often Missed?
Polycystic ovary syndrome is a hormonal condition affecting the ovaries. The name is slightly misleading — not all women with PCOS have cysts, and the core issue is hormonal imbalance rather than anatomy alone. Symptoms include irregular or absent periods, excess androgen (which can cause unwanted hair growth, acne, and hair thinning), weight gain, fertility difficulties, and in some cases, mood disturbances and fatigue.
PCOS is diagnosed using the Rotterdam criteria, which require two of three features: irregular ovulation, elevated androgens, and polycystic ovarian appearance on ultrasound. The condition is the most common cause of irregular periods and female infertility in the UK.
Despite its prevalence, average time to diagnosis in the UK remains long — the Verity APPG report published in September 2025 found that many women wait years for a confirmed diagnosis, often being dismissed or misdiagnosed before a specialist reviews their case. The Royal College of Nursing flagged in February 2026 that PCOS remains significantly underdiagnosed and underdiscussed in primary care settings.
The Ozempic Connection: What the NHS Study Is Exploring
GLP-1 receptor agonists like semaglutide work by mimicking a gut hormone that regulates insulin and appetite. In people with PCOS, insulin resistance is a common feature — many women with the condition have cells that respond poorly to insulin, which in turn drives the androgen overproduction that underlies many PCOS symptoms.
By improving insulin sensitivity, GLP-1 drugs may address one of the root hormonal drivers of PCOS rather than just managing symptoms. Early clinical observations suggest benefits including more regular menstrual cycles, reduced androgen markers, and improved metabolic health.
The NHS-funded study will provide more rigorous evidence. For now, GLP-1 drugs are not an approved standard PCOS treatment on the NHS, and accessing them specifically for PCOS rather than diabetes or obesity is not straightforward. A GP or specialist endocrinologist or gynaecologist would need to assess whether a patient's clinical picture supports a trial of these medications — self-prescribing through online pharmacies carries significant risks for women with PCOS, whose hormonal profile requires careful monitoring.
Upcoming NICE Guidelines: What to Expect
NICE guidelines on PCOS have not been updated comprehensively for several years. The incoming 2026 guidance, prompted partly by the Verity report and parliamentary pressure, is expected to address:
- Faster diagnostic pathways in primary care
- Clearer referral thresholds for specialist assessment
- Expanded treatment options including lifestyle interventions and hormonal therapy
- Mental health support pathways, reflecting the disproportionate rates of anxiety and depression among women with PCOS
When NICE guidelines are updated, they generally shift what GPs are expected to offer at first and second appointment. Women who have previously been told their symptoms do not meet the threshold for referral may find that updated guidelines give them a stronger basis for requesting specialist input.
When to See a GP or Specialist
The NHS advises seeing a GP if you have irregular periods, difficulty getting pregnant, or symptoms of elevated androgens such as excess hair growth, acne, or scalp hair thinning. You do not need a prior PCOS diagnosis to make an appointment — these symptoms are themselves grounds for investigation.
If a GP has already run tests and the results were inconclusive, or if you have a diagnosis but feel your symptoms are not well managed, a referral to a gynaecologist or endocrinologist can provide a more detailed assessment. According to NHS guidance on PCOS, there is no cure for the condition, but treatment can manage individual symptoms effectively — which makes the match between your specific symptom profile and a specialist's expertise important.
Women with PCOS who are also trying to conceive may benefit from input from a reproductive medicine specialist alongside gynaecological care. PCOS is the leading cause of ovulatory infertility, and fertility treatment options — including ovulation induction — are most effectively managed by a specialist who understands the underlying hormonal picture.
ExpertZoom connects UK women with qualified gynaecologists, endocrinologists, and GPs who can advise on women's hormonal health conditions, including PCOS diagnosis and management tailored to your circumstances.
This article provides general health information only. For advice on your individual symptoms or treatment options, consult a qualified GP or specialist.
